Full Program »
123. Associations between Maladaptive Personality Domains and Premature Termination in an Acute Clinical Setting
Personality pathology is typically considered in reference to the diagnosis of dichotomous personality disorders. However, with the inclusion of an Alternative Model of Personality Disorder in DSM-5, empirical investigations of dimensional models of personality pathology have flourished. Pathological personality domains have even been posited as one overarching framework with the potential to streamline conceptualization of both personality- and non-personality-related psychopathology. However, few studies have examined dimensional models of maladaptive personality in relation to (1) clinical outcomes in a naturalistic setting, and (2) using measures short enough to be incorporated into standard clinical care. The goal of the current study, therefore, was to investigate the extent to which domains of personality dysfunction—as measured by the Personality Inventory for DSM-5 Brief Form (PID5 BF)—predicted premature treatment termination among a large sample (N = 2,730) of psychiatric patients referred for treatment at a partial hospital program. Secondarily, we explored the associations between PID-5 BF domains and the length of treatment before both successful and premature termination at the PHP. Individuals who terminated treatment prematurely reported higher levels on all PID-5 domains compared with those who successfully complete treatment. Individuals reporting elevations in the disinhibition and psychoticism domains (i.e., mean scale scores ≥ 2) were twice as likely to terminate prematurely than persons with normative levels. Among successful completers, the antagonism domain was associated with longer treatment length, while detachment was associated with shorter length. These results add to the sparse literature on the clinical utility of the PID-5. Further, they reveal important implications for consideration of personality pathology within diverse clinical populations, the use of the PID-5 BF as one easily administered screening tool in clinical settings, and directions for future research comparing the utility of information gained from such brief measures with that from more exhaustive clinical assessments.